Influenza A and influenza B both cause seasonal flu, produce similar symptoms, and can lead to equally serious illness. The key difference is biological: influenza A is far more genetically diverse, infects both humans and animals, and is the only type capable of triggering pandemics. Influenza B circulates almost exclusively in humans and changes more slowly over time.
How the Two Viruses Are Classified
Influenza A viruses are divided into subtypes based on two proteins on their surface: hemagglutinin (H) and neuraminidase (N). There are 18 known H subtypes and 11 N subtypes, which is where names like H1N1 and H3N2 come from. Only a few of these combinations regularly circulate in people, but the sheer number of possible combinations gives influenza A enormous genetic flexibility.
Influenza B has no subtypes at all. Instead, it’s split into just two lineages: B/Victoria and B/Yamagata. These lineages evolve much more slowly than influenza A subtypes. In recent years, B/Yamagata appears to have stopped circulating entirely, which is why the 2024-2025 seasonal flu vaccine in the United States switched to a trivalent formula containing only one influenza B strain (B/Victoria) alongside two influenza A strains (an H1N1 and an H3N2).
Why Only Flu A Causes Pandemics
Both influenza A and B undergo a process called antigenic drift, where small mutations accumulate as the virus copies itself. These gradual changes are why you can catch the flu more than once and why the vaccine is updated every year. Your immune system’s memory of last year’s virus becomes a little less useful as the virus drifts.
Influenza A, however, can also undergo something called antigenic shift, a sudden, dramatic reshuffling of its surface proteins. This happens because influenza A infects birds, pigs, and other animals in addition to humans. When a virus from an animal population jumps into humans carrying surface proteins people have never encountered, most of the population has zero immunity. That’s how pandemics start. The 2009 H1N1 pandemic, for example, involved a swine-origin virus that made the leap to humans.
Influenza B doesn’t do this. It circulates almost exclusively among humans, so there’s no animal reservoir to generate a radically new version of the virus. Influenza B still causes seasonal outbreaks, but it lacks the mechanism to produce a pandemic.
Symptoms and Severity Are Comparable
If you’re sick with the flu and wondering whether type A or type B is “worse,” the honest answer is that they’re remarkably similar in how they affect adults. A CDC study examining over 24,000 flu-related hospitalizations across eight flu seasons (2005 through 2013) found no significant difference between the two types in ICU admission rates, length of hospital stay, or proportion of deaths among hospitalized adults.
The symptoms themselves are also largely identical: fever, cough, body aches, fatigue, sore throat, and sometimes vomiting or diarrhea. There’s no reliable way to tell influenza A from influenza B based on how you feel. The distinction requires a lab test.
One practical difference is timing. Influenza A tends to dominate the early part of flu season (roughly November through January in the Northern Hemisphere), while influenza B often picks up later, peaking in February or March. Influenza B also tends to hit children particularly hard in some seasons, though both types can cause severe illness in any age group.
How Testing Tells Them Apart
Rapid influenza diagnostic tests, the kind you might get at an urgent care visit, can distinguish between influenza A and influenza B. These tests work by detecting viral proteins from a nasal swab, typically returning results in 15 to 30 minutes. They’re required by the FDA to achieve at least 80% sensitivity for both types compared to the gold-standard molecular test (RT-PCR), along with 95% specificity. That means a positive result is highly reliable, but a negative result doesn’t completely rule out the flu, especially early in the illness.
Molecular tests like RT-PCR are more accurate and can identify the specific subtype or lineage. These are more commonly used in hospitals or during public health surveillance rather than routine office visits.
Treatment Works the Same Way
The antivirals prescribed for flu work against both types. Nearly all recently circulating influenza A and B viruses in the United States remain susceptible to neuraminidase inhibitors (the class that includes the most commonly prescribed flu antiviral) and to newer antiviral options. These medications are most effective when started within 48 hours of symptom onset and can shorten your illness by about a day while reducing the risk of complications.
One older class of antiviral, the adamantanes, is no longer recommended because nearly all circulating influenza A viruses have developed resistance to it. This class never worked against influenza B to begin with, so it’s essentially off the table for seasonal flu treatment entirely.
What This Means for Vaccination
The seasonal flu vaccine is designed to protect against both influenza A and influenza B. For the 2024-2025 season, vaccines include two influenza A components (an H1N1 strain and an H3N2 strain) and one influenza B component (B/Victoria lineage). Previous years used a quadrivalent formula that also included B/Yamagata, but that lineage’s apparent disappearance from global circulation made the fourth component unnecessary.
Because influenza A mutates faster and has more genetic diversity, it’s the harder target for vaccine designers. Influenza A is also the type most likely to produce a strain that doesn’t match the vaccine well in a given year. Still, vaccination reduces your risk of illness from both types and, even when the match isn’t perfect, lowers the chance of severe outcomes like hospitalization.